221 related articles for article (PubMed ID: 19762144)
1. Predicting recurrence and progression of noninvasive papillary bladder cancer at initial presentation based on quantitative gene expression profiles.
Birkhahn M; Mitra AP; Williams AJ; Lam G; Ye W; Datar RH; Balic M; Groshen S; Steven KE; Cote RJ
Eur Urol; 2010 Jan; 57(1):12-20. PubMed ID: 19762144
[TBL] [Abstract][Full Text] [Related]
2. In search of the perfect crystal ball for Ta urothelial cancer.
Chin JL
Eur Urol; 2010 Jan; 57(1):21-2; discussion 23-4. PubMed ID: 19748172
[No Abstract] [Full Text] [Related]
3. Bladder Tumor Subtype Commitment Occurs in Carcinoma
Wullweber A; Strick R; Lange F; Sikic D; Taubert H; Wach S; Wullich B; Bertz S; Weyerer V; Stoehr R; Breyer J; Burger M; Hartmann A; Strissel PL; Eckstein M
Cancer Res; 2021 Mar; 81(6):1552-1566. PubMed ID: 33472889
[TBL] [Abstract][Full Text] [Related]
4. Decreased expression of microRNA-31 associates with aggressive tumor progression and poor prognosis in patients with bladder cancer.
Wang S; Li Q; Wang K; Dai Y; Yang J; Xue S; Han F; Zhang Q; Liu J; Wu W
Clin Transl Oncol; 2013 Oct; 15(10):849-54. PubMed ID: 23408039
[TBL] [Abstract][Full Text] [Related]
5. Telomerase reverse transcriptase promoter mutations in bladder cancer: high frequency across stages, detection in urine, and lack of association with outcome.
Allory Y; Beukers W; Sagrera A; Flández M; Marqués M; Márquez M; van der Keur KA; Dyrskjot L; Lurkin I; Vermeij M; Carrato A; Lloreta J; Lorente JA; Carrillo-de Santa Pau E; Masius RG; Kogevinas M; Steyerberg EW; van Tilborg AA; Abas C; Orntoft TF; Zuiverloon TC; Malats N; Zwarthoff EC; Real FX
Eur Urol; 2014 Feb; 65(2):360-6. PubMed ID: 24018021
[TBL] [Abstract][Full Text] [Related]
6. Prediction of recurrence in low and intermediate risk non-muscle invasive bladder cancer by real-time quantitative PCR analysis: cDNA microarray results.
Mares J; Szakacsova M; Soukup V; Duskova J; Horinek A; Babjuk M
Neoplasma; 2013; 60(3):295-301. PubMed ID: 23452234
[TBL] [Abstract][Full Text] [Related]
7. Expression analysis of VEGF-A and VEGF-B: relationship with clinicopathological parameters in bladder cancer.
Fauconnet S; Bernardini S; Lascombe I; Boiteux G; Clairotte A; Monnien F; Chabannes E; Bittard H
Oncol Rep; 2009 Jun; 21(6):1495-504. PubMed ID: 19424629
[TBL] [Abstract][Full Text] [Related]
8. Gene expression profiling of progressive papillary noninvasive carcinomas of the urinary bladder.
Wild PJ; Herr A; Wissmann C; Stoehr R; Rosenthal A; Zaak D; Simon R; Knuechel R; Pilarsky C; Hartmann A
Clin Cancer Res; 2005 Jun; 11(12):4415-29. PubMed ID: 15958626
[TBL] [Abstract][Full Text] [Related]
9. A proposed score for assessing progression in pT1 high-grade urothelial carcinoma of the bladder.
Raspollini MR; Minervini A; Lapini A; Lanzi F; Rotellini M; Baroni G; Carini M
Appl Immunohistochem Mol Morphol; 2013 May; 21(3):218-27. PubMed ID: 22820663
[TBL] [Abstract][Full Text] [Related]
10. Prognostic Impact of a 12-gene Progression Score in Non-muscle-invasive Bladder Cancer: A Prospective Multicentre Validation Study.
Dyrskjøt L; Reinert T; Algaba F; Christensen E; Nieboer D; Hermann GG; Mogensen K; Beukers W; Marquez M; Segersten U; Høyer S; Ulhøi BP; Hartmann A; Stöhr R; Wach S; Nawroth R; Schwamborn K; Tulic C; Simic T; Junker K; Harving N; Petersen AC; Jensen JB; Keck B; Grimm MO; Horstmann M; Maurer T; Steyerberg EW; Zwarthoff EC; Real FX; Malats N; Malmström PU; Ørntoft TF
Eur Urol; 2017 Sep; 72(3):461-469. PubMed ID: 28583312
[TBL] [Abstract][Full Text] [Related]
11. Papillary Recurrence of Bladder Cancer at First Evaluation after Induction Bacillus Calmette-Guérin Therapy: Implication for Clinical Trial Design.
Mmeje CO; Guo CC; Shah JB; Navai N; Grossman HB; Dinney CP; Kamat AM
Eur Urol; 2016 Nov; 70(5):778-785. PubMed ID: 26922408
[TBL] [Abstract][Full Text] [Related]
12. Predicting disease outcome of non-invasive transitional cell carcinoma of the urinary bladder using an artificial neural network model: results of patient follow-up for 15 years or longer.
Fujikawa K; Matsui Y; Kobayashi T; Miura K; Oka H; Fukuzawa S; Sasaki M; Takeuchi H; Okabe T
Int J Urol; 2003 Mar; 10(3):149-52. PubMed ID: 12622711
[TBL] [Abstract][Full Text] [Related]
13. DNA cytometric features in biopsies of TaT1 urothelial cell cancer predict recurrence and stage progression more accurately than stage, grade, or treatment modality.
Baak JP; Bol MG; van Diermen B; Janssen EA; Buhr-Wildhagen SB; Mestad O; Øgreid P; Kjellevold KH
Urology; 2003 Jun; 61(6):1266-72. PubMed ID: 12809927
[TBL] [Abstract][Full Text] [Related]
14. Photodynamic diagnosis of non-muscle-invasive bladder cancer with hexaminolevulinate cystoscopy: a meta-analysis of detection and recurrence based on raw data.
Burger M; Grossman HB; Droller M; Schmidbauer J; Hermann G; Drăgoescu O; Ray E; Fradet Y; Karl A; Burgués JP; Witjes JA; Stenzl A; Jichlinski P; Jocham D
Eur Urol; 2013 Nov; 64(5):846-54. PubMed ID: 23602406
[TBL] [Abstract][Full Text] [Related]
15. Predicting risk of multiple levels of recurrence and progression after initial diagnosis of nonmuscle-invasive bladder cancer in a multisite, community-based cohort.
Garg T; McMullen CK; Leo MC; O'Keeffe-Rosetti MC; Weinmann S; Nielsen ME
Cancer; 2021 Feb; 127(4):520-527. PubMed ID: 33146913
[TBL] [Abstract][Full Text] [Related]
16. Prognostic significance in substaging ofT1 urinary bladder urothelial carcinoma on transurethral resection.
Chang WC; Chang YH; Pan CC
Am J Surg Pathol; 2012 Mar; 36(3):454-61. PubMed ID: 22261706
[TBL] [Abstract][Full Text] [Related]
17. RUNX3 methylation as a predictor for disease progression in patients with non-muscle-invasive bladder cancer.
Yan C; Kim YW; Ha YS; Kim IY; Kim YJ; Yun SJ; Moon SK; Bae SC; Kim WJ
J Surg Oncol; 2012 Mar; 105(4):425-30. PubMed ID: 22311819
[TBL] [Abstract][Full Text] [Related]
18. HYAL-1 hyaluronidase: a potential prognostic indicator for progression to muscle invasion and recurrence in bladder cancer.
Kramer MW; Golshani R; Merseburger AS; Knapp J; Garcia A; Hennenlotter J; Duncan RC; Soloway MS; Jorda M; Kuczyk MA; Stenzl A; Lokeshwar VB
Eur Urol; 2010 Jan; 57(1):86-93. PubMed ID: 19345473
[TBL] [Abstract][Full Text] [Related]
19. Use of Artificial Intelligence and Machine Learning Algorithms with Gene Expression Profiling to Predict Recurrent Nonmuscle Invasive Urothelial Carcinoma of the Bladder.
Bartsch G; Mitra AP; Mitra SA; Almal AA; Steven KE; Skinner DG; Fry DW; Lenehan PF; Worzel WP; Cote RJ
J Urol; 2016 Feb; 195(2):493-8. PubMed ID: 26459038
[TBL] [Abstract][Full Text] [Related]
20. Association of p53 and p21 expression with clinical outcome in patients with carcinoma in situ of the urinary bladder.
Shariat SF; Kim J; Raptidis G; Ayala GE; Lerner SP
Urology; 2003 Jun; 61(6):1140-5. PubMed ID: 12809883
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
